Zhongxing Jiang

IMM47, a humanized monoclonal antibody that targets CD24, exhibits exceptional anti-tumor efficacy by blocking the CD24/Siglec-10 interaction and can be used as monotherapy or in combination with anti-PD1 antibodies for cancer immunotherapy

D. Liu, Jifeng Yu, Wenzhi Tian, 2023, Antibody therapeutics.

Targeting CD24/Siglec-10 signal pathway for cancer immunotherapy: recent advances and future directions

Jifeng Yu, Wenzhi Tian, Yongping Song, 2024, Cancer immunology, immunotherapy : CII.

A novel anti-LAG-3/TIGIT bispecific antibody exhibits potent anti-tumor efficacy in mouse models as monotherapy or in combination with PD-1 antibody

Jifeng Yu, Binhua Lv, Ildefonso Vicente‐Suarez, 2024, Scientific reports.

Targeting TIGIT for cancer immunotherapy: recent advances and future directions

Jifeng Yu, Xinyuan Liu, Yongping Song, 2024, Biomarker research.

Allogeneic CAR-T cells with of HLA-A/B and TRAC disruption exhibit promising antitumor capacity against B cell malignancies

Zhen Zhang, Y. Ping, Jianmin Huang, 2024, Cancer immunology, immunotherapy : CII.